ADC Therapeutics (ADCT) Competitors $2.39 -0.26 (-9.81%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ADCT vs. NKTR, ITOS, MRSN, CCCC, CTMX, PAHC, IMTX, COLL, SEPN, and AVBPShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Nektar Therapeutics (NKTR), iTeos Therapeutics (ITOS), Mersana Therapeutics (MRSN), C4 Therapeutics (CCCC), CytomX Therapeutics (CTMX), Phibro Animal Health (PAHC), Immatics (IMTX), Collegium Pharmaceutical (COLL), Septerna (SEPN), and ArriVent BioPharma (AVBP). These companies are all part of the "medical" sector. ADC Therapeutics vs. Nektar Therapeutics iTeos Therapeutics Mersana Therapeutics C4 Therapeutics CytomX Therapeutics Phibro Animal Health Immatics Collegium Pharmaceutical Septerna ArriVent BioPharma Nektar Therapeutics (NASDAQ:NKTR) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking. Which has more risk and volatility, NKTR or ADCT? Nektar Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Do insiders and institutionals believe in NKTR or ADCT? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor NKTR or ADCT? Nektar Therapeutics received 575 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.71% of users gave Nektar Therapeutics an outperform vote while only 66.27% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63070.71% Underperform Votes26129.29% ADC TherapeuticsOutperform Votes5566.27% Underperform Votes2833.73% Is NKTR or ADCT more profitable? Nektar Therapeutics has a net margin of -180.70% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% ADC Therapeutics -300.00%N/A -61.33% Does the media refer more to NKTR or ADCT? In the previous week, Nektar Therapeutics had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for ADC Therapeutics. Nektar Therapeutics' average media sentiment score of 0.36 beat ADC Therapeutics' score of 0.28 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NKTR or ADCT? Nektar Therapeutics presently has a consensus price target of $3.50, indicating a potential upside of 227.10%. ADC Therapeutics has a consensus price target of $8.25, indicating a potential upside of 245.19%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, NKTR or ADCT? ADC Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$90.12M2.19-$276.06M-$0.84-1.27ADC Therapeutics$70.72M3.27-$240.05M-$2.39-1.00 SummaryNektar Therapeutics and ADC Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$231.09M$6.49B$5.13B$19.80BDividend YieldN/A8.15%5.18%3.51%P/E Ratio-1.004.8266.7335.39Price / Sales3.27374.171,265.2917.78Price / CashN/A51.8140.2121.45Price / Book-1.349.636.454.64Net Income-$240.05M$154.43M$119.73M$982.94M7 Day Performance-18.43%-9.46%-5.13%-2.12%1 Month Performance-23.89%-7.27%-2.71%-0.39%1 Year Performance239.68%28.13%31.08%23.34% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics2.8286 of 5 stars$2.39-9.8%$8.25+245.2%+275.8%$231.09M$70.72M-1.00310Short Interest ↓NKTRNektar Therapeutics4.2039 of 5 stars$1.17-8.6%N/A+112.0%$215.82M$90.12M-1.39220ITOSiTeos Therapeutics3.0713 of 5 stars$8.46-4.2%N/A-15.9%$308.98M$35M-2.6990Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageMRSNMersana Therapeutics4.3148 of 5 stars$2.52-4.2%N/A+43.5%$322.64M$36.85M-4.13150Analyst ForecastAnalyst RevisionNews CoverageCCCCC4 Therapeutics2.1482 of 5 stars$4.72-8.0%N/A+136.8%$333.19M$20.76M-2.78150Short Interest ↓CTMXCytomX Therapeutics4.4274 of 5 stars$1.00-1.0%N/A-29.5%$78.26M$119.57M5.88170Short Interest ↓Analyst RevisionPAHCPhibro Animal Health4.3687 of 5 stars$24.90-1.5%N/A+132.3%$1.02B$1.02B57.911,940Analyst UpgradeIMTXImmatics2.3143 of 5 stars$8.53-0.5%N/A-3.9%$1.02B$58.44M-9.58260Short Interest ↓COLLCollegium Pharmaceutical4.1071 of 5 stars$30.27+0.3%N/A+17.8%$976.21M$599.25M13.05210SEPNSepternaN/A$22.38-3.6%N/AN/A$974.89MN/A0.00N/APositive NewsAVBPArriVent BioPharma1.029 of 5 stars$28.08-11.9%N/AN/A$943.21MN/A0.0040Analyst ForecastNews Coverage Related Companies and Tools Related Companies NKTR Alternatives ITOS Alternatives MRSN Alternatives CCCC Alternatives CTMX Alternatives PAHC Alternatives IMTX Alternatives COLL Alternatives SEPN Alternatives AVBP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ADCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADCT Stock Alerts